Immunogenicity of Recombinant NC8 Expressing Goose Parvovirus VP2 Gene in BALB/c Mice
Overview
Authors
Affiliations
Goose parvovirus (GPV) continues to be a threat to goose farms and has significant economic effects on the production of geese. Current commercially available vaccines only rarely prevent GPV infection. In our study, NC8 was selected as a vector to express the VP2 gene of GPV, and recombinant pSIP409-VP2/NC8 was successfully constructed. The molecular weight of the expressed recombinant protein was approximately 70 kDa. Mice were immunized with a 2 × 10 colony-forming unit/200 μL dose of the recombinant strain, and the ratios and numbers of CD11c, CD3CD4, CD3CD8, and interferon gamma- and tumor necrosis factor alpha-expressing spleen lymphocytes in the pSIP409-VP2/NC8 group were higher than those in the control groups. In addition, we assessed the capacity of SIP409-VP2/NC8 to induce secretory IgA production. We conclude that administered pSIP409-VP2/NC8 leads to relatively extensive cellular responses. This study provides information on GPV infection and offers a clear framework of options available for GPV control strategies.
The Structural, Biophysical, and Antigenic Characterization of the Goose Parvovirus Capsid.
Jabbari K, Mietzsch M, Hsi J, Chipman P, Qiu J, McKenna R Microorganisms. 2025; 13(1).
PMID: 39858848 PMC: 11768072. DOI: 10.3390/microorganisms13010080.
The Benefits and Applications of in Food and Health: A Narrative Review.
Zare D, Aryaee H, Mirdamadi S, Shirkhan F Iran J Public Health. 2024; 53(10):2201-2213.
PMID: 39544869 PMC: 11557752. DOI: 10.18502/ijph.v53i10.16698.
Eftekhari Z, Doroud D, Tajabadi-Ebrahimi M, Kazemi-Lomedasht F Curr Pharm Des. 2024; 31(3):233-242.
PMID: 39257145 DOI: 10.2174/0113816128310203240823053538.
He G, Long H, He J, Zhu C Probiotics Antimicrob Proteins. 2024; 16(6):2229-2250.
PMID: 39101975 DOI: 10.1007/s12602-024-10338-9.
Suvorov A, Loginova S, Leontieva G, Gupalova T, Desheva Y, Korzhevskii D Vaccines (Basel). 2023; 11(11).
PMID: 38006046 PMC: 10675790. DOI: 10.3390/vaccines11111714.